Cannabinoids (CBD)

SUDA entered into a feasibility study with Zelda Therapeutics for the use of cannabinoids for a range of uses including insomnia, autism, opioid reduction, anxiety, pain and cancer. The study is expected to take 12 months.

SUDA has received its Schedule 9 permit, issued by the Government of Western Australian Department of Health, which authorises the Company to purchase for research and development purposes: cannabidiol, tetrahydrocannabinols and cannabinoids.


Enquire for Further Information